Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8⁺ T cell infiltration and functional transition.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) therapy improves the survival of patients with advanced bladder cancer (BLCA); however, its overall effectiveness is limited, and many patients still develop immunotherapy resistance. The leucine-rich repeat and fibronectin type-III domain-containing protein (LRFN) family has previously been implicated in regulating brain dysfunction; however, the mechanisms underlying the effect of LRFN2 on the tumor microenvironment (TME) and immunotherapy remain unclear.

Methods

Here we combined bulk RNA sequencing, single-cell RNA sequencing, ProcartaPlex multiple immunoassays, functional experiments, and TissueFAXS panoramic tissue quantification assays to demonstrate that LRFN2 shapes a non-inflammatory TME in BLCA.

Results

First, com

SUBMITTER: Yu A 

PROVIDER: S-EPMC10565151 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature